Corporate Governance and Financial Developments – Integrated Hitech Limited

On 30 May 2026, the board of directors of Integrated Hitech Limited convened at the company’s registered office to deliberate on a series of governance and financial matters pertinent to the quarter and fiscal year ending 31 March 2026. The session, documented in a formal board minutes record, encompassed the following key actions and disclosures:

1. Audit and Financial Reporting

  • Approval of Audited Results – The board formally approved the audited financial statements for the quarter and the full year ended 31 March 2026. These statements were submitted pursuant to SEBI Regulation 33 and accompanied by the auditor’s unmodified opinion and a statutory declaration confirming compliance with Indian Accounting Standards (Ind AS).
  • Compliance with Listing Obligations – The audit opinion reaffirmed that the financials present a true and fair view, and that no material discrepancies were identified. Consequently, the company’s adherence to the applicable listing requirements on the stock exchange remains intact.
  • Internal Audit Appointment – In accordance with the recommendations of the audit committee, Mr Nitin Oza was appointed as the company’s internal auditor for the fiscal year 2026‑27. Mr Oza will oversee internal control frameworks and risk management processes, ensuring continued alignment with best governance practices.

2. Director Resignation

  • Resignation of Mrs. Rainy Ramesh Singhi – The board recorded the resignation of Non‑Executive, Non‑Independent Director Mrs Rainy Ramesh Singhi, effective 26 March 2026. She cited other professional commitments as the principal reason for stepping down. The board expressed gratitude for her contributions and acknowledged the need to appoint a suitable replacement to maintain board diversity and expertise.
  • NCLT Petition Withdrawal – A circular resolution was noted in which the company withdrew its petition (CP(CA)/105/CHE/2025) filed before the National Company Law Tribunal (NCLT) in Chennai under Section 66 of the Companies Act, 2013. This action reflects a strategic decision to streamline legal matters and concentrate on core business activities.

Cross‑Sector Update – Johnson & Johnson’s Phase 1/1b CHRYSALIS‑2 Findings

In a separate corporate announcement, Johnson & Johnson (J&J) reported early-stage clinical results for its RYBREVANT + LAZCLUZE combination therapy, targeting advanced non‑small‑cell lung cancer (NSCLC). The data, presented at the 2026 American Society of Clinical Oncology (ASCO) conference, highlighted:

  • Median Overall Survival – An encouraging median overall survival of approximately 3.5 years, signalling potential long‑term benefit in this patient population.
  • EGFR Mutation Response – Consistent therapeutic responses observed across atypical epidermal growth factor receptor (EGFR) mutation subgroups, suggesting broad applicability of the regimen.
  • Market Impact – Despite the positive interim analysis, Johnson & Johnson experienced a modest decline in its share price at the close of trading on the day of the announcement, reflecting investor caution amid the broader oncology market volatility.

Analytical Perspective

From a governance standpoint, Integrated Hitech’s proactive measures—auditor appointments, board composition adjustments, and legal petition withdrawal—demonstrate a disciplined approach to compliance and risk mitigation. The net loss recorded for the year does not undermine the audited compliance with Ind AS, underscoring the importance of robust internal controls rather than headline profitability alone.

Johnson & Johnson’s phase‑I findings, while sector‑specific to oncology, exemplify the intersection of therapeutic innovation and market dynamics. Positive survival outcomes can translate into valuation gains, but short‑term share price reactions often mirror broader industry sentiment and competition.

These developments collectively illustrate how firms across distinct sectors—technology‑driven manufacturing versus biopharmaceutical—navigate regulatory frameworks, internal governance, and market perceptions, all within the prevailing macroeconomic backdrop of 2026.